Results 251 to 260 of about 101,286 (277)

Ipilimumab/nivolumab/nivolumab/prednisone

Reactions Weekly, 2023
openaire   +1 more source

Ipilimumab/nivolumab/nivolumab/pembrolizumab

Reactions Weekly, 2023
openaire   +1 more source

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Nature Medicine, 2021
Tina Cascone, William N William, Annikka Weissferdt   +2 more
exaly  

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nature Medicine, 2022
Nazli Dizman, Luis Meza, Tanya B Dorff
exaly  

Ipilimumab/nivolumab/nivolumab

Reactions Weekly
  +4 more sources

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Nature, 2022
Kohei Shitara, Jaffer A Ajani, Lucjan S Wyrwicz   +2 more
exaly  

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Nature Medicine, 2022
Robyn P M Saw, Ellen H W Kapiteijn, Astrid A M Van Der Veldt   +2 more
exaly  

Immunotherapies for hepatocellular carcinoma

Nature Reviews Clinical Oncology, 2021
, Florian Castet, Mala K Maini
exaly  

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Nature Medicine, 2022
Lacey J Padrón, Eileen M O'reilly, Christopher R Cabanski   +2 more
exaly  

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Nature, 2022
Rodabe N Amaria, MERRICK ROSS, Carlos A Torres-Cabala   +2 more
exaly